Endocrine Abstracts

Objective: This study aims to investigate whether DHEAS (Dehydroepiandrostenedione sulfate) inhibit the growth of leiomyoma.

Method: Total 131 patients were recruited according to the leiomyoma size by transvaginal ultrasonography. Excluding twenties and over fifties, 88 patients were analyzed. The leiomyoma group was classified into three groups, such as mild, moderate and severe. The mild group was defined as the presence of at least one or two leiomyomas smaller than 3 cm in diameter. The moderate group was defined as having of at least one 3 to 5 cm leiomyoma. The severe group was defined as having leiomyomas greater than 5 cm. The control group was defined as no presence of leiomyoma. Serum DHEAS level was measured by radioimmunoassay.

Results: DHEAS mean value of four groups are control (n=19, 125.7±77.6), mild (n=24, 122.4±72.3), moderate (n=24, 90.6±40.2) and severe (n=21, 87.7±43.8) (P=0.069). Comparing after recombination four group into two group, control plus mild (group 1) and moderate plus severe (group 2 n=45), their mean values are group 1 (n=43, 123.9±73.8) and group 2 (n=45, 89.2±41.5) (P=0.0076).

Conclusion: This study shows that DHEAS may inhibit the growth of leiomyoma.

Keywords: Leiomyoma, DHEAS (dehydroepiandrosterone sulfate), RIA (radioimmunoassay).